Plain-English translation of NCT06504290 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Schizophrenia research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called VV119 to see if it is safe, well-tolerated, and effective for treating schizophrenia. The study has two parts: first, researchers give the medication to healthy adults to make sure it is safe, and then they test it in patients who have been diagnosed with schizophrenia. Participants will receive gradually increasing doses of the medication to find the right balance between benefit and side effects.
Schizophrenia is a serious mental health condition, and researchers are always looking for new treatment options that might work better or have fewer side effects than existing medications. This trial will help doctors understand whether this medication could be a helpful new choice for patients.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will either be a healthy volunteer or a patient with schizophrenia. Healthy volunteers will visit the clinic to receive gradually increasing doses of the medication under close medical supervision to ensure it is safe. Patients with schizophrenia will participate in a similar process across multiple clinic locations, where they will receive the medication and be monitored for both safety and how well it helps their symptoms. Throughout the study, you will have regular check-ups, blood tests, and assessments to track how you are responding to the treatment.
AI-generated summary from trial data · Jun 20, 2026 · Not medical advice
China